June 24 (Reuters) - Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday.

Biotech IPOs have shown signs of a rebound this year, but a string of poor post-debut performances have tempered expectations of a full market recovery.

The company is looking to raise as much as $317.7 million by offering nearly 17.7 million shares at a price range of $16 and $18 each.

Alumis expects to list on the Nasdaq Global Market under the symbol "ALMS".

Morgan Stanley, Leerink Partners, Cantor Fitzgerald and Guggenheim Securities are the underwriters for the offering. (Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Sriraj Kalluvila and Shailesh Kuber)